Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome

Mohamad Cherry, Marylou Cardenas-Turanzas, Hannah Pham, Hagop Kantarjian, Jorge Cortes, Sherry Pierce, Lingsha Zhou, Srdan Verstovsek

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The clinical relevance of prior malignancy (PM) in patients with essential thrombocythemia (ET) and polycythemia vera (PV) is largely unknown. We retrospectively evaluated 437 patients (ET, n= 263; PV, n= 174) treated at MD Anderson between 1960 and 2010. Forty-four patients had PM (ET, 10%; PV, 11%), with median time to diagnosis of 66 months. PM was not associated with abnormal cytogenetics, JAK2-mutation frequency, blood-cell counts or progression to acute leukemia or myelofibrosis. In multivariate analysis, only older age and high LDH levels were associated with worse OS. In conclusion, PM does not predict worse outcomes for patients with ET and PV.

Original languageEnglish (US)
Pages (from-to)1472-1476
Number of pages5
JournalLeukemia Research
Volume37
Issue number11
DOIs
StatePublished - Nov 2013

Keywords

  • Essential thrombocythemia
  • Myeloproliferative disorders
  • Polycythemia vera
  • Prior malignancy
  • Transformation to acute leukemia
  • Transformation to myelofibrosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome'. Together they form a unique fingerprint.

  • Cite this